Ka-onLi

Partner

Silicon Valley + 1.650.739.3916

Ka-on Li works closely with clients to successfully structure and execute IP, technology, and commercial transactions to achieve high-stakes business objectives. She is an experienced IP and technology lawyer whose practice focuses on transactions for clients active in the technology, medical, pharmaceutical, life sciences, data analytics, food and beverage, retail, consulting, financial, fashion, consumer goods, telecommunications, media, and entertainment fields. Ka-on drafts and negotiates contracts involving outsourcing, IP development, licensing and commercialization, distribution arrangements, software and cloud-related matters, infrastructure and telecommunications projects, and manufacturing and supply services.

Ka-on has solid experience in assisting emerging and established businesses at a strategic level in U.S. and overseas markets. She has represented software and life science companies at all stages, from formation to exit. She has drafted and negotiated some of the most significant collaborations and strategic agreements and alliances between industry entrepreneurs, service providers, acquirers, and investors. Much of her experience involves working on deals involving the development and commercialization of products driven by the convergence of multiple technologies, such as digital health, fintech, and AI-driven platforms.

She has acted for clients on a full range of M&A and financing transactions involving domestic and foreign IP and technology assets on the buy-side and the sell-side. Representative clients include SAP, Cardinal Health, Astellas, The Riverside Company, GE, Verizon, and Blackberry.

Ka-on's deep and diverse experience, including her secondment at Australia's largest telecommunications provider for more than a year, enables her to bring a pragmatic, business-oriented and collaborative approach to her work and negotiations.

Esperienze

  • Affiliate of Centre Lane Partners acquires appliance business from Instant BrandsJones Day advised an affiliate of Centre Lane Partners in the acquisition and financing of the appliances business of Instant Brands, designer and distributor of kitchen and home appliances, including the Instant Pot, pursuant to Section 363 of title 11 of the United States Code.
  • VSE acquires assets and license from HoneywellJones Day advised VSE Corporation in the $105 million asset purchase and perpetual license agreement to manufacture and support certain of Honeywell International’s fuel control systems on four key engine platforms.
  • FLEETCOR acquires PayByPhoneJones Day advised FLEETCOR Technologies, Inc. in the acquisition of PayByPhone, a global provider of digital parking payment solutions.
  • Asbury Automotive Group acquires Jim Koons AutomotiveJones Day is advising Asbury Automotive Group, Inc. (NYSE: ABG), one of the largest automotive retail and service companies in the U.S., in its definitive agreement with the Jim Koons Automotive Group of Companies to acquire Jim Koons Automotive for approximately $1.2 billion in cash.
  • restor3d acquires Conformis, Inc.Jones Day advised restor3d, Inc., a leading personalized 3D-printed orthopedic company, on its acquisition of Conformis, Inc. (NASDAQ: CFMS), a leading medical technology company focused on orthopedic patient care.
  • Roper Technologies subsidiary acquires business of RepliconJones Day advised Roper Technologies, Inc. in the acquisition by subsidiary Deltek, the leading global provider of software and solutions for project-based businesses, of the business of Replicon, Inc., a provider of unified time tracking solutions that bring together Project Delivery, Finance, and HR on a single platform, purpose-built for project and services-centric organizations.
  • Five9 acquires Aceyus for $82 millionJones Day represented Five9, Inc. in its acquisition of 100% of the equity of Aceyus, Inc. for $82 million in cash.
  • Sumitomo acquires assets and rights related to lefamulin from NabrivaJones Day advised Sumitomo Pharma Co., Ltd. in the acquisition of assets from Nabriva Therapeutics plc and various wholly-owned subsidiaries. This acquisition includes assets from the U.S., Ireland, and Austria in support of the development, manufacture, marketing and commercialization of lefamulin in the People’s Republic of China, Hong Kong, Macau and Taiwan.
  • Riverside sells Baker Hill to Flexpoint FordJones Day represented The Riverside Company in connection with the sale of portfolio company Baker Hill, a provider of cloud-based, end-to-end loan origination, risk management, and analytics software, to Flexpoint Ford.
  • Astellas acquires Iveric bioJones Day advised Astellas Pharma Inc. in the $5.9 billion cash acquisition of Iveric bio, Inc., a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.
  • Cardinal Health merges its Outcomes™ business into Transaction Data SystemsJones Day advised Cardinal Health, Inc. (NYSE: CAH) in connection with the combination of its Outcomes™ business to Transaction Data Systems, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a minority stake in the combined entity.
  • VSE Corporation partners with The Loar Group to acquire Desser AerospaceJones Day advised VSE Corporation (NASDAQ: VSEC) ("VSE") in its acquisition (the "Acquisition") of Desser Aerospace ("Desser") for a purchase price of $124 million.
  • ABS sells technical inspection service line to ApaveJones Day advised ABS Group of Companies, Inc. in the sale by one of its subsidiaries, ABSG Consulting, Inc., of its technical inspection service line to Apave Group, an international inspection group.
  • Ansys acquires DiakoptoJones Day advised Ansys in the acquisition of Diakopto, a provider of differentiated EDA solutions to accelerate integrated circuit (IC) development.
  • Applus Technologies sold to Opus InspectionJones Day advised Applus Servicios Tecnologicos, S.L.U. in the sale of one of its U.S. subsidiaries, Applus Technologies Inc., to Opus Inspection, Inc.
  • Rich Data Co partners with nCino to enhance lending process using AIJones Day advised Rich Data Co (RDC), an industry leading artificial intelligence (AI) decisioning platform, in connection with a value-added reseller agreement with nCino, Inc., to enhance the lending process for their mutual customers.
  • Meridian Bioscience agrees to be acquired by SD Biosensor and SJL Partners in $1.53 billion all-cash transactionJones Day advised Meridian Bioscience, Inc. in its $1.53 billion all-cash acquisition by SD Biosensor and SJL Partners.
  • Accelmed Partners makes $35 million investment in SKNV Inc.Jones Day advised Accelmed Partners in its $35 million investment in SKNV Inc., a full continuum-of-care dermatology digital health company for in-practice dispensing and ecommerce of customized prescriptions and skincare.
  • Glennis Solutions, Enquire, and Sherpa CRM join forces to create market-leading senior living software platformJones Day is advising Glennis Solutions in its merger with Enquire and Sherpa supported by a strategic investment from Rubicon Technology Partners, a leading private equity firm based in Boulder, Colo., that is focused exclusively on investing in and growing enterprise software companies.
  • CDPQ leads $125 million Series D financing of Soli OrganicJones Day advised CDPQ as lead investor in the $125 million Series D financing of Soli Organic, the nation's only soil-based, indoor farming company delivering 100% USDA certified organic produce.
  • Seminari e convegni

    • January 19, 2022
      AI in Drug Discovery and Development